US Patent

US9180090 — Non-sedating antihistamine injection formulations and methods of use thereof

Method of Use · Assigned to JDP Therapeutics Inc · Expires 2030-02-11 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects injectable formulations of cetirizine hydrochloride for treating acute allergic reactions and methods for administering them.

USPTO Abstract

Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions.

Drugs covered by this patent

cetirizine-hydrochloride (CETIRIZINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2635`	—	cetirizine-hydrochloride

Patent Metadata

Patent number: US9180090
Jurisdiction: US
Classification: Method of Use
Expires: 2030-02-11
Drug substance claim: No
Drug product claim: No
Assignee: JDP Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.